CMX 2043

Drug Profile

CMX 2043

Alternative Names: CMX-2043

Latest Information Update: 09 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ischemix
  • Class Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Reperfusion injury

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2016 The phase IIa CARIN trial in Reperfusion injury (Prevention) did not meet the pre-specified endpoints
  • 09 Dec 2015 Ischemix receives patent allowance for CMX-2043 in New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top